Quick Takeaways
- KAPA - Kairos Pharma, LTD. has 8 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 8 Insiders of Kairos Pharma, LTD.
- Symbol
- KAPA on NYSE
- Location
- Los Angeles, CA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 16 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Kairos Pharma, LTD. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| John S. Yu | CEO and Chairman, Director, 10%+ Owner | $6,101,344 | Mixed | 08 Oct 2025 | ||
| Neil Bhowmick | Chief Scientific Officer | $931,334 | Mixed | 08 Oct 2025 | ||
| Ramachandran Murali | VP of Research and Development | $329,481 | Mixed | 08 Oct 2025 | ||
| Doug Samuelson | Chief Financial Officer | $322,342 | Mixed | 08 Oct 2025 | ||
| Rahul Singhvi | Director | $54,124 | Mixed | 08 Oct 2025 | ||
| Hyun W. Bae | Director | $52,092 | Mixed | 16 Sep 2025 | ||
| Hansoo Michael Keyoung | Director | $31,992 | Mixed | 16 Sep 2025 | ||
| Rosemary Mazanet | Director | Mixed | 16 Sep 2024 |
Top shareholders of Kairos Pharma, LTD. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| John S. Yu |
3/4/5
|
CEO and Chairman, Director, 10%+ Owner |
31%
|
5,546,677
|
$6,101,344 | — | 08 Oct 2025 | |
| Neil Bhowmick |
3/4/5
|
Chief Scientific Officer |
7.4%
|
1,311,739
|
$931,334 | — | 08 Oct 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
884,938
|
$628,306 | -$576,510 | 30 Jun 2025 | |
| Ramachandran Murali |
3/4/5
|
VP of Research and Development |
1.7%
|
299,529
|
$329,481 | — | 08 Oct 2025 | |
| Doug Samuelson |
3/4/5
|
Chief Financial Officer |
1.7%
|
293,039
|
$322,342 | — | 08 Oct 2025 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.3%
|
231,878
|
$129,620 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.63%
|
111,290
|
$62,210 | — | 31 Mar 2026 | |
| Rahul Singhvi |
3/4/5
|
Director |
0.28%
|
49,204
|
$54,124 | — | 08 Oct 2025 | |
| Hyun W. Bae |
3/4/5
|
Director |
0.41%
|
73,370
|
$52,092 | — | 16 Sep 2025 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.36%
|
63,884
|
$35,711 | — | 31 Mar 2026 | |
| Hansoo Michael Keyoung |
3/4/5
|
Director |
0.16%
|
29,084
|
$31,992 | — | 16 Sep 2025 | |
| SevenBridge Financial Group, LLC |
13F
|
Company |
0.25%
|
44,286
|
$30,331 | — | 31 Mar 2026 | |
| Aptus Capital Advisors, LLC |
13F
|
Company |
0.25%
|
44,286
|
$24,756 | — | 31 Mar 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.22%
|
39,543
|
$22,105 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
0.14%
|
24,100
|
$13,472 | — | 31 Mar 2026 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.12%
|
21,575
|
$12,000 | — | 31 Mar 2026 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.09%
|
16,247
|
$9,082 | — | 31 Mar 2026 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
3,962
|
$2,215 | — | 31 Mar 2026 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
10
|
$6 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Kairos Pharma, LTD.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Neil Bhowmick | KAPA | COMMON STOCK | Award | 15.1% | 171,756 | 1,311,739 | 08 Oct 2025 | Direct | ||
| Hyun W. Bae | KAPA | COMMON STOCK | Award | 35.2% | 19,084 | 73,370 | 08 Oct 2025 | Direct | ||
| Ramachandran Murali | KAPA | COMMON STOCK | Award | 104% | 152,672 | 299,529 | 08 Oct 2025 | Direct | ||
| Hansoo Michael Keyoung | KAPA | COMMON STOCK | Award | 190.8% | 19,084 | 29,084 | 08 Oct 2025 | Direct | ||
| Rahul Singhvi | KAPA | COMMON STOCK | Award | 63.4% | 19,084 | 49,204 | 08 Oct 2025 | Direct | ||
| Doug Samuelson | KAPA | COMMON STOCK | Award | 108.8% | 152,672 | 293,039 | 08 Oct 2025 | Direct | ||
| John S. Yu | KAPA | COMMON STOCK | Award | 486% | 190,840 | 230,105 | 08 Oct 2025 | Direct | ||
| Hyun W. Bae | KAPA | COMMON STOCK | Award | 22.6% | 10,000 | 54,286 | 16 Sep 2025 | Direct | ||
| Hansoo Michael Keyoung | KAPA | COMMON STOCK | Award | 10,000 | 10,000 | 16 Sep 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.